Gilead Sciences, Inc. (GILD)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
At close: 04:00PM EST
Pre-Market:
| Previous Close | 77.65 |
| Open | 77.29 |
| Bid | 0.00 x 800 |
| Ask | 0.00 x 1000 |
| Day's Range | 77.16 - 78.47 |
| 52 Week Range | 72.87 - 89.74 |
| Volume | |
| Avg. Volume | 5,733,264 |
| Market Cap | 97.615B |
| Beta (5Y Monthly) | 0.31 |
| PE Ratio (TTM) | 16.78 |
| EPS (TTM) | 4.67 |
| Earnings Date | Jan 31, 2024 - Feb 05, 2024 |
| Forward Dividend & Yield | 3.00 (3.83%) |
| Ex-Dividend Date | Dec 14, 2023 |
| 1y Target Est | 89.76 |
Simply Wall St.Is Gilead Sciences, Inc.'s (NASDAQ:GILD) ROE Of 26% Impressive?
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like...
ACCESSWIREGilead Employees Stitch Together To Create a Special Panel of the AIDS Quilt
NORTHAMPTON, MA / ACCESSWIRE / December 1, 2023 / Nearly 36 years ago the AIDS Memorial Quilt was displayed for the first time to memorialize and physically represent lives lost to HIV. Gilead has always actively supported the Quilt, and creating ...
Business WireGilead’s Leadership in Metastatic Breast Cancer Showcased With New Trodelvy Data at San Antonio Breast Cancer Symposium 2023
FOSTER CITY, Calif., November 30, 2023--Gilead Sciences, Inc. (Nasdaq: GILD) today announced it will present new data at San Antonio Breast Cancer Symposium (SABCS) 2023, supporting the use of Trodelvy® (sacituzumab govitecan-hziy) in certain metastatic triple-negative breast cancer (mTNBC) and pre-treated HR+/HER2- metastatic breast cancer (mBC) patients.
© 2023 Yahoo. All rights reserved.